Patients with essential hypertension undergo endothelial dysfunction, particularly in the conduit arteries. Cilostazol, a type III phosphodiesterase inhibitor, serves a role in the inhibition of platelet aggregation and it is widely used in the treatment of peripheral vascular diseases. Previous studies have suggested that cilostazol suppresses endothelial dysfunction; however, it remains unknown whether cilostazol protects the endothelial function in essential hypertension. The aim of the present study was to investigate whether, and how, cilostazol suppresses angiotensin II (angII)-induced endothelial dysfunction. Human umbilical vein endothelial cells (HUVECs) and Sprague Dawley rats were exposed to angII and treated with cilostazol. Endothelial cell apoptosis and function, nitric oxide and superoxide production, phosphorylation (p) of Akt, and caspase-3 protein expression levels were investigated. AngII exposure resulted in the apoptosis of endothelial cells in vitro and in vivo. In vitro, cilostazol significantly suppressed the angII-induced apoptosis of HUVECs; however, this effect was reduced in the presence of LY294002, a phosphoinositide 3 kinase (PI3K) inhibitor. Furthermore, cilostazol suppressed the angII-induced p-Akt downregulation and cleaved caspase-3 upregulation. These effects were also alleviated by LY294002. In vivo, cilostazol suppressed the angII-induced endothelial cell apoptosis and dysfunction. Cilostazol was also demonstrated to partially reduced the angII-induced increase in superoxide production. The results of the present study suggested that cilostazol suppresses endothelial apoptosis and dysfunction by modulating the PI3K/Akt pathway.
Introduction
The endothelium lies in between the circulating blood and vascular smooth muscle cells, which are responsible for peripheral resistance (1) . It may be easily damaged and endothelial dysfunction occurs in the pathogenesis of various cardiovascular complications, particularly in hypertension (2) (3) (4) (5) (6) . Damage to the endothelium can result in a positive feedback mechanism as in arterial hypertension, as it negatively affects the vascular tone and homeostasis upon damage. Thus, it is an early independent predictor of cardiovascular events (7) (8) (9) (10) . Endothelial dysfunction contributes to an increase in large arterial stiffness in patients with isolated systolic hypertension, resulting in impaired vascular elasticity and compliance, and subsequent arterial hypertension (11, 12) . Endothelial dysfunction increases the risk of developing atherosclerotic lesions and related cardiovascular events, even if the blood pressure of patients with essential hypertension is controlled (13) . Restoration of conduit artery endothelial function is therefore a primary target in limiting cardiovascular morbidity and mortality in patients with essential hypertension (7) .
Cilostazol, a type III phosphodiesterase inhibitor, inhibits platelet aggregation and it is widely used in the treatment of peripheral vascular diseases (14) (15) (16) . Previous studies have demonstrated that cilostazol serves a role in the inhibition of endothelial cell apoptosis (14, 17) . For example, it can suppress superoxide production and expression of adhesion molecules in human endothelial cells (18) . In addition, cilostazol may prevent endothelial cell apoptosis by stimulating the extracellular signal-regulated kinase (ERK) 1/2 and p38 MAPK signaling, particularly in patients with hyperlipidemia and in pathological tissue conditions, including ischemia, shock and sepsis (19, 20) . Previous studies have suggested that the phosphoinositide 3 kinase (PI3K)/Akt pathway serves an important role in preventing cell apoptosis induced by numerous stimuli (21, 22) . In endothelial cells, PI3K/Akt activation promotes cell survival (2, 23) . Previous studies have demonstrated that cilostazol produces a vasculo-angiogenic effect by upregulating a broad signaling network that includes the PI3K/Akt/endothelial nitric oxide synthase (eNOS) pathway (17) . However, whether and how cilostazol protects the endothelial function in patients with essential hypertension remains unknown. The aim of the present study was to determine whether cilostazol suppresses endothelial cell apoptosis and dysfunction in hypertension, and whether the PI3K/Akt pathway was involved. Evidence from previous studies suggest that angiotensin II (angII), a peptide of the rennin angiotensin system, exerts an vasoconstrictive effect, induces intracellular reactive oxygen species (ROS) production and causes vascular dysfunction and arterial hypertension (24) (25) (26) (27) (28) (29) (30) . Therefore, Sprague Dawley (SD) rats were infused with angII to generate hypertension. The effect of cilostazol on endothelial function and apoptosis, as well as nitric oxide (NO) and superoxide production were investigated. Additionally, the PI3K/Akt signaling pathway was also investigated using human umbilical vein endothelial cells (HUVECs). Animal model and experimental design. Male SD rats (weight, 200-220 g; age, 10-12 weeks) were purchased from the Animal Center of The Fourth Military Medical University (FMMU). They were maintained in a temperature-controlled room (24˚C), on a 12 h light/dark cycle and given free access to food water. The experimental protocol was approved by the Institutional Care and Use Committee of the FMMU, which conforms to the Guidelines for the Care and Use of Laboratory Animals of the US National Institutes of Health (NIH publication no. 85-23, revised 1996) (31) . Rats were divided into four groups (n=10): (i) Saline-treated group, rats treated with saline by intragastric administration (IA); (ii) Saline + Cilo-treated group, rats treated with saline and cilostazol (30 mg/kg/day) by IA; (iii) angII-treated group, rats continuously infused with angII (1,000 ng/kg/min) by subcutaneously implanted Alzet osmotic pumps (2004 model; Cupertino, CA, USA) as previously described (32) ; and (iv) angII (1,000 ng/kg/min) + Cilo-treated group, rats treated with cilostazol (30 mg/kg/day) in addition to angII (1,000 ng/kg/min) infusion.
Cilostazol suppresses angiotensin II-induced apoptosis in endothelial cells

Materials and methods
Chemicals
After 4 weeks of angII infusion and cilostazol administration, rats were anesthetized with an intraperitoneal injection of sodium pentobarbital (45 mg/kg; Shanghai Rongbai Biological Technology Co., Ltd., Shanghai, China). Hemodynamic measurements were obtained as previously described (33) . In brief, the right carotid artery of anesthetized rats was cannulated with a catheter connected to a microtip pressure transducer (Chengdu Instrument Factory, Chengdu, China) and the transducer was connected to a recording system (Rm6280C, Biological Instruments). The systolic and diastolic blood pressure (sBP and dBP, respectively) were then measured. Finally, the rats were sacrificed by cervical vertebral dislocation. The abdominal aortae were removed and divided into two sections by transverse section. The first was incubated in 10% buffered formalin (Sangon Biotech Co., Ltd., Shanghai, China) for 24 h and then paraffin-embedded (Sangon Biotech Co., Ltd.) for further assessment of apoptosis. The second was used for the detection of endothelium-dependent and -independent vasorelaxation, and assessment of superoxide anion and NO production.
Detection of endothelium-dependent and independent vasorelaxation. Abdominal aortae were carefully dissected and mounted as ring preparations of ~3 mm on hooks in individual organ baths (Radnoti Glass Technology, Monrovia, CA, USA). Arterial integrity was assessed first by stimulation of vessels with 120 mM KCl, and then washed three times in physiological salt solution (130 mM NaCl, 14.9 mM NaHCO 3 , 4.7 mM KCl, 1.18 mM KH 2 PO 4 , 1.18 mM MgSO 4 7H 2 O, 1.56 mM CaCl 2 H 2 O, 0.026 mM EDTA and 5.5 mM glucose). The temperature was maintained at 37˚C and 95% O 2 and 5% CO 2 was pumped into the physiological salt solution. Following washing and stabilization, by contracting the segments with phenylephrine (10 µmol/l), followed by relaxation with Ach (10 µmol/l). The contraction response was detected using an organ chamber containing an isometric Mulvany-Halpern myograph (model 610; DMT-USA, Inc., Marietta, GA, USA) and recorded using a PowerLab 8/SP data acquisition system (ADInstruments Ltd., Colorado Springs, CO, USA), as previously described (34) (35) (36) . Contractile responses of abdominal aortic rings were evoked with 30 nmol/l U46619. At the plateau of contraction, Ach (1x10 -8 -1x10 -4 mol/l) or SNP (1x10 -10 -1x10 -6 mol/l)were progressively added to the organ bath to induce endothelium-dependent or -independent relaxation.
Detection of superoxide anion production. Superoxide anions from the aortae were measured using flow injection chemiluminescence, as previously described (37) . The superoxide anion concentration is reported as chemiluminescence intensity (CI) per mg of tissue weight.
Detection of total NO production. The total NO production in aortae was determined by measuring nitrite concentration, as previously described (37) . The concentration of nitrite was calculated from a nitrite standard curve.
Immunohistochemistry. Tissue samples were prepared from abdominal aortae. After being paraffin-embedded, the abdominal aorta was exposed by a transverse section and cut into 4 µm thick sections. The cell nuclei of the sections were stained with DAPI as previously described (26) . The immunofluorescence data were analyzed using an Eclipse Ni-E microscope (Nikon, Tokyo, Japan) and NIS-elements imaging software (Nikon).
Cell culture and treatment. HUVECs were provided by Dr. Xiaofei Zhu from the Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University (Xi'an, China). HUVEC monolayers were grown as previously described (2, 20) . In brief, cells were plated into dishes with Gibco Dulbecco's Modified Eagle's medium (Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 1% penicillin-streptomycin (Beyotime Institute of Biotechnology, Shanghai, China) and 10% fetal bovine serum (Beyotime Institute of Biotechnology), under 5% CO 2 at 37˚C, at a density of 1x10 5 cells/ml. Cells were supplemented with 5 U/ml heparin (Sangon Biotech Co., Ltd.) and 100 ng/ml endothelial cell growth substance (Collaborative Research Inc., Bedford, MA, USA). When the cells reached confluence (90%), subcultures were prepared. Cells in actively growing conditions between the third and fifth passages were used for further experiments.
HUVECs were divided into four parallel groups: Untreated cells (control group); cells treated with 10 µmol/l angII (angII-treated group); cells pretreated with 10 µmol/l cilostazol prior to incubation with angII (angII + Cilo-treated group); and cells pretreated with a combination of cilostazol and LY294002 (a PI3K inhibitor) prior to incubation with angII (angII + Cilo + LY-treated group). The concentrations of cilostazol and angII were selected on the basis of previous studies (20, 24) .
Immunocytochemistry. Cultured HUVECs were fixed with 10% buffered formalin and permeabilized with 0.5% Triton X-100 (Sangon Biotech Co., Ltd.). The cell nuclei were stained with DAPI as previously described (33) .
Western blot analysis of HUVECs. Cultured HUVECs in lysis buffer containing 50 mmol/l Tris-hydrochloride, 150 mmol/l sodium chloride, 1% Nonidet P-40, 0.25% superoxide dismutase, 1 mmol/l EDTA, 1 mmol/l NaF, 1 mmol/l Na 3 VO 3 , 1 mM phenylmethylsulfonyl f luoride and a proteinase inhibitor cocktail tablet (Roche Diagnostics, Basel, Switzerland). Protein samples were assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, as described previously (33) . In brief, total protein concentration of each sample was determined prior to polyacrylamide gel electrophoresis, followed by the transfer of proteins to polyvinylidene fluoride (PVDF) membranes (Sangon Biotech Co., Ltd.). PVDF membranes were incubated with blocking buffer (LI-COR Biosciences, Lincoln, NE, USA) for 1 h at room temperature and subsequently immunoblotted with either of the following primary antibodies: Polyclonal rabbit total Akt (1:1,000; cat. no. SAB4500797; Sigma-Aldrich, St. Louis, MO, USA); polyclonal rabbit phosphorylated-Akt (p-Akt) (1:1,000; cat. no. SAB4504017; Sigma-Aldrich); cleaved and total monoclonal rabbit caspase-3 (1:1,000; cat. no. 9665; Cell Signaling Technology, Inc., Danvers, MA, USA); and monoclonal mouse β-actin (1:10,000; cat. no. A5441; Sigma-Aldrich). β-actin protein expression served as a loading control. Following being immunoblotted with primary antibodies overnight at 4˚C, the PVDF membranes were washed three times (10 min each) in Tris-buffered saline containing Tween-20 and then incubated with IRDye 680RD goat anti-rabbit IgG (1:5,000; cat. no. 925-68071; LI-COR Biosciences) or IRDye 800CW goat anti-mouse IgM (1:5,000; cat. no. 926-32280; LI-COR Biosciences) for 60 min at room temperature, separately. The PVDF membranes were then washed three times (10 min each) in phosphate-buffered saline with Tween 20. Bands were evaluated by densitometry using an Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE, USA). detected by microscopy (Eclipse Ni-E; Nikon). The apoptotic index is expressed as the number of positively stained cells per total number of endothelial cells.
Statistical analysis. Data are presented as the mean ± standard error of the mean. SPSS 13.0 software (SPSS, Inc, Chicago, IL, USA) was used to analyze the data. One-way analysis of variance was used to determine statistically significant differences among the four groups. P<0.05 was considered to indicate a statistically significant difference.
Results
AngII-infusion increases the sBP and dBP levels in treated rats.
Previous studies have demonstrated that angII infusion at doses between 175 and 1,000 ng/kg/min may result in hypertension in rats (32, 38, 39) . In order to demonstrate the hypertensive effect of angII, a dose of 1,000 ng/kg/min was infused into rats for the period of 4 weeks. Following the infusion, the sBP and dBP levels were measured and demonstrated to be significantly increased compared with the saline-treated group ( * P<0.05; Table I ). Cilostazol was not identified to exhibit an effect on angII-infusion-dependent hypertension (Table I) .
Cilostazol treatment inhibits angII-induced dysfunction and apoptosis of endothelial cells.
Evidence from previous studies has suggested that angII induces aberrant oxidative stress in the vascular wall and, therefore, intracellular ROS production, resulting in excessive apoptosis and dysfunction of the epithelium and endothelium (40) (41) (42) . Whether cilostazol suppresses angII induced endothelial dysfunction remains unknown. Thus, the percentage of Ach-induced vascular relaxation was investigated (Fig. 1) . Compared with the saline-treated rats, abdominal aorta rings from the angII-infused rats demonstrated significantly impaired Ach-induced endothelium-dependent relaxation ( * P<0.05; Fig. 1 ). Cilostazol significantly reduced the impairment in vasorelaxation in the angII +Cilo-treated group compared with the angII-treated group ( # P<0.05; Fig. 1 ). No significant difference among the four groups of rats was identified upon investigation of SNP-induced endothelium-independent relaxation (Fig. 2) .
Furthermore, the apoptosis of endothelial cells was investigated. Compared with the saline-treated group, endothelial apoptosis was significantly increased in the angII-infused rats ( * P<0.05; Fig. 3 ). Endothelial apoptosis was significantly decreased in angII-infused rats treated with cilostazol compared with the angII-treated group ( # P<0.05; Fig. 3 ). The cilostazol + saline-treatment had no effect on endothelial apoptosis (Fig. 3) or the Ach-induced vasorelaxation (Fig. 1) . These results suggest that cilostazol alleviates the endothelial dysfunction in angII-induced hypertension rats, possibly through an anti-apoptotic effect.
Effect of cilostazol on the angII-induced increase in super-
oxide anion production. AngII acts via the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-derived 
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ROS to trigger endothelial cell apoptosis and impair endothelium-dependent relaxation (34) . Cilostazol may therefore alleviate endothelial cell apoptosis and attenuate impairment in vasorelaxation by inhibiting superoxide production. Thus, the superoxide levels produced in the aortic tissue from the four groups of treated rats were determined and compared. AngII significantly increased the superoxide production compared with the saline-treated group ( * P<0.05; Fig. 4 ). However, cilostazol significantly suppressed the superoxide anion production compared with the angII-only treated group ( # P<0.05; Fig. 4) .
Effect of cilostazol on NO production. To detect whether cilostazol has an effect on NO production and thus improves vasorelaxation in response to Ach, total NO production in aortae was determined from the concentration of nitrite, a stable metabolite of NO in vitro (38) . AngII significantly increased the total NO production compared with the saline-treated, control group ( * P<0.05; Fig. 5 ). Cilostazol had no effect on the angII-induced NO production.
Inhibition of angII-induced HUVEC apoptosis by cilostazol.
AngII treatment (10 µmol/l) resulted in a significant increase in the number of TUNEL-positive (apoptotic) HUVECs compared with the control group ( * P<0.05; Fig. 6 ). Pretreatment with cilostazol (10 µmol/l) reduced the number of TUNEL-positive HUVECs produced on exposure to angII, compared with the Cilostazol (1, 10 and 100 µmol/l) was administered to HUVECs to investigate the effect concentration. Cilostazol at 1 µmol/l mildly inhibited angII-induced HUVEC apoptosis, compared with concentrations of 10 or 100 µmol/l which significantly attenuated apoptosis, to similar levels, in the angII treated group ( * P<0.05; Fig. 7) .
Effect of cilostazol on Akt and cleaved caspase-3 protein expression levels in HUVECs.
To elucidate the mechanism underlying the cilostazol-dependent reduction of angII-induced apoptosis, the effect of cilostazol on Akt phosphorylation was examined using western blot analysis (Fig. 8A) . As demonstrated in Figure 8B , angII significantly reduced the phosphorylation of Akt compared with the control group ( * P<0.05) and cilostazol attenuated the reduction of Akt phosphorylation compared with the angII-treated group ( # P<0.05). Furthermore, the effect of cilostazol on Akt phosphorylation was reduced by combinational treatment with LY294002 compared with the angII + Cilo-treated group ( η P<0.05; Fig. 8B ).
AngII treatment upregulated the cleaved caspase-3 protein expression levels compared with the control group ( * P<0.05; Fig. 8C ) and cilostazol treatment suppressed this effect compared with the angII-treated group ( # P<0.05; Fig. 8C ). LY294002 attenuated the effect of cilostazol on cleaved caspase-3 protein expression compared with the angII + Cilo-treated group ( η P<0.05; Fig. 8C ).
Discussion
The results of the present study demonstrated that cilostazol suppressed the endothelial cell apoptosis induced by angII, in vivo and in vitro. In vivo, cilostazol suppressed the angII-induced endothelial dysfunction and increase in superoxide production, without affecting the total NO production. In vitro, cilostazol suppressed the angII-induced upregulation of cleaved caspase-3 protein levels and increase A previous study demonstrated that patients with essential hypertension suffer from endothelial dysfunction, particularly in the conduit arteries, due to damage from abnormal blood pressure (43) . In turn, a damaged endothelium has a negative effect on the vascular tone, homeostasis and arterial stiffness. The endothelial dysfunction elevates the risk of cardiovascular events in patients with essential hypertension, whether the blood pressure is controlled or not (13) . Endothelial cell apoptosis can induce endothelium dysfunction, therefore, its prevention may improve endothelial function and decrease the risk of cardiovascular disease (41) . AngII is important in the pathogenesis of hypertension (44) and increased levels of angII promote the formation of atherosclerotic lesions (45) . Previous experimental studies have indicated that atherosclerotic lesion-prone vascular regions are characterized by a high endothelial cell turnover, which has been attributed to an increased rate of endothelial cell apoptosis (30, 46) . Thus, angII-induced endothelial cell apoptosis may serve an essential role in endothelial dysfunction in patients with essential hypertension. In the present study, angII was validated as a useful tool to induce hypertension and endothelial apoptosis in rats. The results of the present study demonstrated that angII treatment led to hypertension, endothelial dysfunction, an increase in superoxide production and endothelial apoptosis, consistent with previous studies (39, (47) (48) (49) (50) .
Cilostazol is a type III phosphodiesterase inhibitor and serves a role in the inhibition of endothelial cell apoptosis (14, 17) . Thus, patients suffering from hypertension may benefit from administration of this drug, although the efficacy and mechanism of action in patients with hypertension have not yet been determined. In the present study, the effect of cilostazol on angII-induced (hypertensive) endothelial apoptosis and endothelial function was investigated. Cilostazol treatment suppressed the angII-induced endothelial dysfunction and apoptosis in vivo without affecting the blood pressure.
Vascular relaxation critically depends on the balance between superoxide and NO production by the vascular endothelium (51) . Therefore, the superoxide anion and NO production was detected in the aortae of treated rats. Cilostazol attenuated the angII-induced increase in superoxide anion production, however had no effect on NO production. It may be considered controversial that angII increased the NO production and suppressed endothelial function, compared with cilostazol treatment which improved the endothelial function without affecting the NO production. However, these results may be due to the actions of different NO synthases (NOS), as endothelial NOS (eNOS) and inducible NOS (iNOS) serve different roles in the pathophysiology of cardiovascular diseases (52) (53) (54) . Relatively low concentrations of NO appear to favor cell proliferation and anti-apoptotic responses compared with higher levels of NO which favor pathways inducing cell cycle arrest, mitochondrial respiration and apoptosis (55) . Under pathological conditions increased amounts of NO are produced, resulting in stimulation of iNOS expression, and possibly endothelial dysfunction (56, 57) . Further research is required to assess this effect.
In order to further investigate the mechanisms involved in the protective effects of cilostazol against endothelial apoptosis, HUVECs were utilized as an experimental tool. In vitro, cilostazol significantly reduced the angII-induced HUVEC apoptosis. Additionally, cilostazol attenuated the angII-induced reduction in Akt phosphorylation, and this protective effect of cilostazol on HUVEC apoptosis was inhibited by LY294002. The PI3K/Akt pathway is considered to be an important pathway for cell survival (58, 59) , particularly in endothelial cells (2) . Caspase-3 serves as a central member of the apoptotic cascade and can be activated to cleave the inhibitor of endonuclease, which cuts the DNA and induces the final stage of apoptosis. The present study demonstrated that angII treatment led to an upregulation of cleaved caspase-3 and further treatment with cilostazol downregulated the cleaved caspase-3 in angII-treated cells.
In conclusion, cilostazol protects HUVECs from apoptosis by stimulating the PI3K/Akt pathway and inhibiting the caspase pathway. As indicated in Figure 9 , the results of the current study suggest that cilostazol demonstrated a protective role against endothelial apoptosis by affecting the PI3K/AKt pathway and the superoxide anion/NO balance in animals suffering from angII-induced hypertension. Cilostazol may therefore represent a novel therapeutic agent for patients with essential hypertension. 
